Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type- I/ B# ~+ c) b6 Z* T' v8 Q: `
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 8 H0 s' L( x, h* o# T7 v, s
+ Author Affiliations
! s. f j& D3 t4 j6 v9 C0 d* d9 Q) |. |( I7 N+ ]: A) Z
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 0 | y0 ~0 H# Z
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
3 j$ r" f) W# d# {. B4 S3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 a& G( I* ?6 d1 L+ i7 w% l2 i5 E
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 1 t4 @8 D: ~- U4 N3 L
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
" W& c7 L' B+ @1 k* G! h9 E6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
/ S$ |8 ]5 R. [6 R/ }7Kinki University School of Medicine, Osaka 589-8511, Japan
+ M$ Z9 ^+ Q* d+ u- v& g8Izumi Municipal Hospital, Osaka 594-0071, Japan 1 @4 w2 p' k, B( K
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan ' ~% T- X2 A! `5 t# |6 Z
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp * {, Z% m% s; z
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. % t+ L* U' c1 K7 i& L3 u/ |4 ~
7 X2 g% G- u b4 z" [+ S% H0 Z0 X
|